Clindamycin-resistant Clostridioides difficile: a challenge in dentistry

Małgorzata Bernatek; Henning Sommermeyer; Hanna Pituch; Dorota Wultańska; Zygmunt Kopczyński; Jacek Piątek; Paulina Wojtyła-Buciora

doi:10.5114/jhi.2022.117343

eISSN: 2450-5722
ISSN: 2450-5927

Journal of Health Inequalities

Current issue Archive Online first About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2022
vol. 8

Send email

Copy url:

abstract:

Original paper

Clindamycin-resistant Clostridioides difficile: a challenge in dentistry

Małgorzata Bernatek

¹

,

Henning Sommermeyer

¹

,

Hanna Pituch

²

,

Dorota Wultańska

²

,

Zygmunt Kopczyński

¹

,

Jacek Piątek

¹

,

Paulina Wojtyła-Buciora

^{1, 3}

Department of Health Sciences, Calisia University, Kalisz, Poland
Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland
Department of Physiology, Poznan University of Medical Sciences, Poland

J Health Inequal 2022; 8 (1): 82–88

DOI: https://doi.org/10.5114/jhi.2022.117343

Online publish date: 2022/06/30

View full text Get citation

PlumX metrics:

Introduction
Clindamycin is frequently prescribed in dentistry. The spread of clindamycin resistance among Clostridioides difficile strains and associated severe side effects have triggered patients’ concern. The extent of this concern and how it is addressed were investigated in this study. Pro- or synbiotics have been suggested to prevent antibiotic-induced C. difficile infection (CDI). In vitro experiments were performed to evaluate what role these products can play in managing clindamycin-resistant CDI and which product features might be beneficial.

Material and methods
A survey among German dentists evaluated the importance of side effects of antibiotics during discussions with patients, clindamycin usage and whether co-administration of pro- or synbiotics is recommended. Three different C. difficile strains were characterized by antibiotic susceptibility testing (AST) and the possibility to inhibit their in vitro growth by products containing probiotic microorganisms.

Results
All respondents claimed that side effects of antibiotics are a topic of discussion with patients, 92% reported using clindamycin. 6% of respondents stated that they did not recommend pro- or synbiotics, while 67% claimed to make this recommendation with each antibiotic prescription. AST of the three investigated C. difficile strains revealed resistance against clindamycin (and other antibiotics) of the C. difficile ribotype 001 strain No. 977 and the ribotype 027 strain No. 644. In vitro inhibition experiments showed that all three strains could be best inhibited by multi-strain synbiotic preparations.

Conclusions
The recommendation to co-administer pro- or synbiotics together with clindamycin can be used to address concerns of patients. The results of this study support this approach and provide some guidance for product selection.

keywords:

clindamycin, Clostridioides difficile, gut-microbiome, multi-drug resistance, PCR ribotype 027

Journal published under the patronage of:

Clindamycin-resistant Clostridioides difficile: a challenge in dentistry

Małgorzata Bernatek 1 , Henning Sommermeyer 1 , Hanna Pituch 2 , Dorota Wultańska 2 , Zygmunt Kopczyński 1 , Jacek Piątek 1 , Paulina Wojtyła-Buciora 1, 3

clindamycin, Clostridioides difficile, gut-microbiome, multi-drug resistance, PCR ribotype 027

Małgorzata Bernatek

¹

,

Henning Sommermeyer

¹

,

Hanna Pituch

²

,

Dorota Wultańska

²

,

Zygmunt Kopczyński

¹

,

Jacek Piątek

¹

,

Paulina Wojtyła-Buciora

^{1, 3}